Brian Rini, MD (@brian_rini) ranks #19 among US gu cancer KOLs on X in 2026, by engagement from fellow physicians. 35 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $57,333 in 2025 general payments.
At a Glance
- GU Cancer: US #19 · 35 physicians engaged
- Presented at ASCO 2026 in 2026
- CMS Open Payments lists $57,333 in 2025 general payments.
This Month
What Brian Rini, MD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| GU Cancer | #19 | — | 35 | 38 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Brian Rini, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ASCO 2026 · DiscussantLiving Longer, Living Better: Can We Have It All? (GU session)Source: @nataliagandur on X ↗
What Colleagues Are Saying About Brian Rini, MD
2026 posts by fellow physicians that mention @brian_rini, quoted word for word.
Triplets in 1st line RCC failed in LS12 @Annals_Oncology @brian_rini (n=1500!). There are not many combinations with HIF/VEGF/PD1 left to test and this approach has probably run its course. It’s time for a new chapter in RCC with T cell engagers and bispecifics #ESMO26 @montypal @DrChoueiri @OncoAlert
A standout discussion from @brian_rini at #ASCO26: "Living Longer, Living Better — Can We Have It All?" 👏 A masterclass in turning data into the questions that actually matter for patients 🧠 Highlights that resonated: 🔹 A clarifying framework for the 3 components of peri-operative therapy in urothelial cancer — neoadjuvant, bladder-directed, adjuvant — and where ctDNA/imaging might guide us 🔹 RAD-IO in context: 12-mo DFS (84%) compares favorably to modern peri-op regimens, but follow-up is short in a curable disease⏳ 🔹 RAMPART: adjuvant IO is active in resected #RCC — but whether CTLA-4 adds benefit remains unclear, and we need OS + non-clear cell data ⏳ 🔹 A provocative, much-needed take on QOL: existing tools don't fully capture the patient experience — patient-defined toxicity categories & regret scores deserve prospective study 🎯 His parting message hit home: peri-operative EVP is transformative, and patients will accept real toxicity to be cured of MIBC. The challenge ahead is measuring "living better" in ways that truly reflect the patient experience 🙌 #KidneyCancer #BladderCancer #GUOnc #GUOncology @ASCO @urotoday @JCOOP_ASCO @kcCURE @OncoAlert
Nice one table summary by @brian_rini putting today’s LITESPARK-011 results (presented just now @GU26) in context. @Uromigos @DukeCancer https://t.co/Yu2GLbnB7R
Brian Rini, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Combination therapy is emerging as a standard in refractory RCC. Combos increase tumor shrinkage endpoints. TKI provides early disease control. CRs are possible but is cure? Toxicity consideration is critical in this setting. Biomarkers to guide choice of drug(s) are needed https://t.co/L4aS8y69bG
Industry Payments
CMS Open Payments · 2025 general payments
$57,333 across 35 payments